Is the price fair?
What MESO's price assumes
Mesoblast Limited did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 621× revenue.
621
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 10.1
Price / book · as of 2023-Q1
- EV / sales
- 629
EV / sales
Details›
- Price / book2023-Q1
- 10.1
- EV / sales2023-Q1
- 629
- Market capitalisation
- $1.86B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
The closest names by size in the same industry